The FDA has approved a new type of schizophrenia drug that may change the way the disorder is treated.
Adam Feuerstein is a Senior Writer and National Biotech Columnist for STAT, with his work also appearing in the Boston Globe Technology. He specializes in covering the biopharmaceutical industry, providing analysis and insights on CEOs, drug developments, mergers and acquisitions, and other significant events within the field. Adam's articles offer a comprehensive perspective on the latest trends and advancements in biotech.